RIRobert J. Isfort

Robert J. Isfort

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Robert J. Isfort has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Proteomic analysis of rat soleus muscle undergoing hindlimb suspension-induced atrophy and reweighting hypertrophy

    by Robert J. Isfort, Feng Wang, Kenneth D. Greis, Yiping Sun, Thomas W. Keough, Roger P. Farrar, Sue C. Bodine, N. Leigh Anderson

    A proteomic analysis was performed comparing normal rat soleus muscle to soleus muscle that had undergone either 0.5, 1, 2, 4, 7, 10 and 14 days of hindlimb suspension‐induced atrophy or hindlimb suspension‐induced atrophied soleus muscle that had undergone 1 hour, 8 hour, 1 day, 2 day, 4 day and 7 days of reweighting‐induced hypertrophy. Muscle mass measurements demonstrated continual loss of soleus mass occurred throughout the 21 days of hindlimb suspension; following reweighting, atrophied soleus muscle mass increased dramatically between 8 hours and 1 day post reweighting. Proteomic analysis of normal and atrophied soleus muscle demonstrated statistically significant changes in the relative levels of 29 soleus proteins. Reweighting following atrophy demonstrated statistically significant changes in the relative levels of 15 soleus proteins. Protein identification using mass spectrometry was attempted for all differentially regulated proteins from both atrophied and hypertrophied soleus muscle. Five differentially regulated proteins from the hindlimb suspended atrophied soleus muscle were identified while five proteins were identified in the reweighting‐induced hypertrophied soleus muscles. The identified proteins could be generally grouped together as metabolic proteins, chaperone proteins and contractile apparatus proteins. Together these data demonstrate that coordinated temporally regulated changes in the skeletal muscle proteome occur during disuse‐induced soleus muscle atrophy and reweighting hypertrophy.


  • Proteomic analysis of rat soleus and tibialis anterior muscle following immobilization

    by Robert J Isfort, Feng Wang, Kenneth D Greis, Yiping Sun, Thomas W Keough, Sue C Bodine, N.LEigh Anderson


  • Skeletal muscle hypertrophy and anti‐atrophy effects of clenbuterol are mediated by the β2‐adrenergic receptor

    by Richard T. Hinkle, Karen M.B. Hodge, David B. Cody, Russell J. Sheldon, Brian K. Kobilka, Robert J. Isfort

    Analyses were performed to evaluate the roles of the β1‐ and β2‐adrenergic receptors in the skeletal muscle hypertrophy and anti‐atrophy response to the β‐adrenergic agonist, clenbuterol. Treatment of wild‐type mice with clenbuterol resulted in statistically significant hypertrophy of the innervated tibialis anterior and medial gastrocnemius muscles and inhibition of denervation‐induced atrophy of these muscles. Treatment of β1‐adenergic receptor knockout mice with clenbuterol also resulted in statistically significant hypertrophy of the innervated tibialis anterior and medial gastrocnemius muscles and inhibition of denervation‐induced atrophy of these muscles. In contrast, in β2‐adrenergic receptor knockout mice and in mice lacking both the β1‐ and β2‐adrenergic receptors, clenbuterol treatment did not result in hypertrophy of the innervated tibialis anterior and medial gastrocnemius muscles, nor did it inhibit denervation‐induced atrophy in these muscles. Together these data demonstrate that the β2‐adrenergic receptor is responsible for both the skeletal muscle hypertrophy and anti‐atrophy effects of the β‐adrenergic agonist clenbuterol. © 2002 Wiley Periodicals, Inc. Muscle Nerve 25: 000–000, 2002


  • Mechanisms of Cell Transformation in the Syrian Hamster Embryo (SHE) Cell Transformation System

    by Robert J. Isfort

    Abstract:The Syrian hamster embryo (SHE) cell transformation system has been used for investigational studies of basic mechanisms of neoplastic transformation, as well as determining the carcinogenic potential of chemical, physical, and biological agents. Many of these investigations utilize an intermediate step in the SHE cell neoplastic transformation process, known as morphological transformation, as an indicator that the cells have acquired an increased potential to progress to malignancy. While the nature of the morphologically transformed phenotype is not completely understood, it is believed to result from a block in the cellular differentiation of stem cells present within the SHE cell population. In terms of determination of the transforming potential of biological/chemical/physical agents, more than 500 agents have been tested in the SHE cell transformation assay with an 80–90% correlation between MT and carcinogenic potential. As such, the SHE cell transformation assay has utility as a test to provide short‐term information on the carcinogenic potential of chemicals. One class of agents of current interest with regard to SHE cell transformation assay utilization consists of growth and differentiation factors (GDFs). Analysis of the SHE cell transformation potential of the GDFs, epidermal growth factor (EGF), fibroblast growth factor 4 (FGF‐4), platelet‐derived growth factor AA (PDGF AA), PDGF AB, PDGF BB, and the antimitogenic GDF, transforming growth factor beta one (TGF‐β1), was performed. All GDFs, with the exception of TGF‐β1, induced SHE cell transformation. However, an interesting difference between the GDFs was observed‐PDGF A/B and PDGF B/B, but not PDGF A/A, EGF, or FGF‐4, induced transformation after both a transient 1‐day exposure and a continuous 7‐day exposure, while continuous 7‐day exposure was required for transformation by PDGF A/A, EGF, and FGF‐4. interestingly, both transient 1‐day and continuous 7‐day TGF‐β1 exposure resulted in suppression of transformation induced by a variety of transforming agents including growth factors, Ames assay‐positive carcinogens, Ames assay‐negative carcinogens, and spontaneous transformation. Interestingly TGF‐β1 was not able to suppress transformation by the tumor promoter, TPA. Together, these data demonstrate the utility of the Syrian hamster embryo cell transformation system for analyzing the transforming potential of GDFs and for characterizing differences in transforming mechanisms between different GDFs.


  • Proteomic analysis of the atrophying rat soleus muscle following denervation

    by Robert J. Isfort, Richard T. Hinkle, Melissa B. Jones, Feng Wang, Kenneth D. Greis, Yiping Sun, Thomas W. Keough, N. Leigh Anderson, Russell J. Sheldon

    A proteomic analysis was performed comparing normal rat soleus muscle to denervated soleus muscle at 0.5, 1, 2, 4, 6, 8 and 10 days post denervation. Muscle mass measurements demonstrated that the times of major mass changes occurred between 2 and 4 days post denervation. Proteomic analysis of the denervated soleus muscle during the atrophy process demonstrated statistically significant (at the p < 0.01 level) changes in 73 soleus proteins, including coordinated changes in select groups of proteins. Sequence analysis of ten differentially regulated proteins identified metabolic proteins, chaperone and contractile apparatus proteins. Together these data indicate that coordinated temporally regulated changes in the proteome occur during denervation‐induced soleus muslce atrophy, including changes in muscle metabolism and contractile apparatus proteins.


  • Confirmed identies of proteins from a two-dimensional map of Syrian hamster embryo cells

    by Thomas N. Asquith, Dorothy L. Gauggel, Ricardo Esquer-Blasco, N. Leigh Anderson, Robert J. Isfort